Revance Releases Third Quarter 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Revance Therapeutic (RVNC) PT Lowered to $42 at Mizuho Securities
November 2, 2018 7:25 AM EDTMizuho Securities analyst, Difei Yang, lowered the price target on Revance Therapeutic (NASDAQ: RVNC) to $42.00 (from $48.00) while maintaining a Buy rating following the company's 3Q earnings report. Revance reported 3Q EPS of $(0.91) that is slightly above FactSet consensus of $(0.92). $2.4 mil of revenue was... More
Revance Therapeutics (RVNC) Tops Q3 EPS by 6c
November 1, 2018 4:58 PM EDTRevance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($0.91), $0.06 better than the analyst estimate of ($0.97).
"We look forward to an impactful fourth quarter," said Dan Browne, president and chief executive officer at Revance. "In addition to the initiation of two new Phase 2... More
